Alpine Immune Sciences, Inc. (NASDAQ:ALPN) Short Interest Update

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) saw a significant growth in short interest in December. As of December 31st, there was short interest totalling 1,020,000 shares, a growth of 118.0% from the December 15th total of 467,800 shares. Based on an average trading volume of 93,300 shares, the short-interest ratio is presently 10.9 days. Approximately 7.5% of the shares of the stock are short sold.

NASDAQ ALPN opened at $10.41 on Friday. The company has a 50-day simple moving average of $12.49 and a two-hundred day simple moving average of $10.81. The company has a quick ratio of 2.87, a current ratio of 2.87 and a debt-to-equity ratio of 0.04. Alpine Immune Sciences has a 12-month low of $7.87 and a 12-month high of $15.14. The firm has a market cap of $304.18 million, a price-to-earnings ratio of -6.02 and a beta of 1.76.

Alpine Immune Sciences (NASDAQ:ALPN) last posted its quarterly earnings results on Tuesday, November 9th. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.01 by ($0.56). Alpine Immune Sciences had a negative net margin of 169.03% and a negative return on equity of 58.85%. The business had revenue of $8.52 million for the quarter, compared to analysts’ expectations of $22.30 million. Equities analysts expect that Alpine Immune Sciences will post -1.73 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently bought and sold shares of ALPN. JPMorgan Chase & Co. purchased a new stake in shares of Alpine Immune Sciences during the second quarter worth about $40,000. Barclays PLC boosted its holdings in shares of Alpine Immune Sciences by 223.1% during the third quarter. Barclays PLC now owns 4,747 shares of the biotechnology company’s stock worth $51,000 after purchasing an additional 3,278 shares during the period. New York State Common Retirement Fund purchased a new stake in shares of Alpine Immune Sciences during the second quarter worth about $93,000. California State Teachers Retirement System purchased a new stake in shares of Alpine Immune Sciences during the second quarter worth about $145,000. Finally, HighVista Strategies LLC purchased a new stake in shares of Alpine Immune Sciences during the third quarter worth about $152,000. Institutional investors and hedge funds own 96.80% of the company’s stock.

Separately, Zacks Investment Research upgraded shares of Alpine Immune Sciences from a “strong sell” rating to a “hold” rating in a research report on Monday, November 29th.

Alpine Immune Sciences Company Profile

Alpine Immune Sciences, Inc is a development-stage pharmaceutical company, which engages in the discovering of protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. Its product pipeline includes inflammatory diseases; immuno-oncology; and engineered cellular therapies.

Featured Story: What Is an EV Stock

Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.